ImageneBio (IMA) Non-Current Deffered Revenue (2020 - 2025)

ImageneBio has reported Non-Current Deffered Revenue for 4 years, with the latest figure at $52000.0 in Q3 2025.

• Quarterly Non-Current Deffered Revenue changed N/A year-over-year to $52000.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $52000.0 (changed N/A YoY) and the FY2021 annual result came in at $7.7 million, down 78.15% from the prior year.
• Non-Current Deffered Revenue retreated to $52000.0 in Q3 2025 per IMA's latest filing, from $2.5 million in the prior quarter.
• Over five years, Non-Current Deffered Revenue peaked at $30.0 million in Q1 2021 and troughed at $52000.0 in Q3 2025.
• A 3-year average of $12.2 million and a median of $6.2 million in 2021 frame the typical range for Non-Current Deffered Revenue.
• The sharpest annual moves came in 2021 and 2022: Non-Current Deffered Revenue slumped 78.15% in 2021, then sank 88.84% in 2022.
• Over 3 years, Non-Current Deffered Revenue stood at $7.7 million in 2021, then tumbled by 67.41% to $2.5 million in 2022, then sank by 97.92% to $52000.0 in 2025.
• According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $52000.0, $2.5 million, and $3.8 million for Q3 2025, Q3 2022, and Q2 2022 respectively.